In Segment A, individuals will get various doses and schedules of oral ABBV-744 tablet to detect Protected dosing routine. Supplemental participants will likely be enrolled within the identified monotherapy dosign routine. In Section B, members will acquire oral ruxolitinib and ABBV-744 will probably be supplied as "increase-on" therapy. In Phase https://peterj777erf3.hyperionwiki.com/user